The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents

Autor:	Salem Y Mohamed, Waseem M. Seleem, Amr Shaaban Hanafy
Rok vydání:	2018
Předmět:	business.industry hemic and lymphatic diseases Immunology General Engineering Thrombotic thrombocytopenic purpura medicine General Earth and Planetary Sciences medicine.disease business Direct acting General Environmental Science
Zdroj:	african journal of gastroenterology and hepatology. 1:1-9
ISSN:	2735-5497 2735-5489
Popis:	Background and aim Experts have reported thrombocytopenia linked to chronic liver disease in up to 70% in patients with advanced fibrosis and portal hypertension. Thrombotic thrombocytopenic purpura (TTP) occurrence with HCV infection is a rare and life-threatening event. We aimed to investigate the cause of disturbed conscious level, acute hemolytic anemia, and severe thrombocytopenia in a male patient with chronic HCV and under treatment with direct-acting antivirals. Case report: Development of severe thrombocytopenia, acute hemolytic anemia, neurological symptoms in the form of fits and coma in a 32- year- old man with chronic HCV infection after one week of treatment with direct-acting antivirals (sofosbuvir 400mg PO daily, and daclatasvir 60 mg PO daily). Brain CT was normal, with a negative Coombs test and the presence of schistocytes in the peripheral blood smear. The patient presentation was suggestive of thrombotic thrombocytopenic purpura (TTP). Conclusion: This is a case of TTP after one week of direct-acting antiviral drugs despite the safety profile of these medications. Studying the pathophysiology of TTP after DAAs needs more clarifications.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::59dda3409c443fdf2376f6808e2cfc2f https://doi.org/10.52378/kxkq8987 Zobrazit plný text záznamu